• About Us
    • Fact Checking Policy
    • Ownership & funding information
    • Volunteer
  • Subscribe
  • Letter submission
    • Submissions Policy
  • Contact Us
The Online Citizen Asia
  • Opinion
    • Editorial
    • Commentaries
    • Letters
    • Comments
  • Current Affairs
    • Singapore
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Arts & Culture
    • Consumer Watch
    • NGO
    • Lifestyle
    • Travel
  • Politics
    • Civil Society
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
No Result
View All Result
  • Opinion
    • Editorial
    • Commentaries
    • Letters
    • Comments
  • Current Affairs
    • Singapore
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Arts & Culture
    • Consumer Watch
    • NGO
    • Lifestyle
    • Travel
  • Politics
    • Civil Society
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
No Result
View All Result
The Online Citizen Asia
No Result
View All Result

TB drug price slashed in global push to thwart killer disease

by onlinecitizen
02/11/2019
in Health, International
Reading Time: 3 mins read
0

Hand of unknown female doctor holding a vial of medicine for Tuberculosis disease (Photo by Creativa Images from Shutterstock).

by Glenda KWEK

A pharmaceutical multinational on Thursday slashed the price of a key anti-tuberculosis drug boosting the battle against the world’s deadliest infectious disease, as a new treatment was also set to begin extensive testing.
The initiatives came as the United Nations seeks to galvanise the campaign against TB, which killed 1.5 million people worldwide last year and saw 10 million more infected.
“This lifesaving drug has, until now, been completely unaffordable in developing countries,” said Lelio Marmora, head of Unitaid, a global health initiative that helped broker the landmark deal, which will see the Sanofi company cut the price of its rifapentine drug by two thirds.
The cheaper price will apply in 100 of the world’s poorest nations. South Africa, where TB is a big killer, will roll out the drug from next year, Unitaid’s programme director Robert Matiru told AFP.
Other major markets that could take up the treatments include India, which has a quarter of the world’s TB cases, Indonesia, Philippines and Kenya, Sanofi’s global health business chief Thibaud Lefort told AFP.
“We are looking realistically next year at adding at least five major countries and a dozen other smaller countries accelerating their efforts,” he said.

TB resistance

Lefort said his firm welcomed generic versions of the drug being produced.
Aid agencies have become increasingly frustrated at the slow pace of fighting the disease, which the UN hopes to eradicate by 2030.
The existing TB vaccine is almost a century old and only good for limited numbers of patients and forms of the illness.
The battle has been held up by some TB strains becoming resistant to drugs.
“The reason drug-resistant TB is such a problem is because it is so much more difficult to treat, it costs so much more to treat and also… the morbidity and mortality is much higher,” NIH’s Peter Kim told AFP.
Rifapentine, combined with the drug isoniazid, not only treats patients with TB, but also shields a person who is infected but not yet sick from developing the disease.
With one quarter of the world’s population carrying the TB infection, and up to 10 percent of them going on to develop the chronic lung disease, experts say preventive drugs such as rifapentine are central to eradicating the illness.
Only 1.8 million people are on preventive TB therapies, but a UN health summit last year set a target of 30 million people to be on such drugs by 2022, Matiru said.
Activists at a global lung health conference in Hyderabad, also called for the price of tests used for TB diagnosis to be halved to $5 to make it more affordable for poorer nations.
The price cut follows an announcement earlier this week by Britain’s GlaxoSmithKline that a new vaccine tested in adults in three African nations had shown particular promise.
The treatment had 50 percent effectiveness three years after it was given to participants in Kenya, South Africa and Zambia who already have TB bacteria but have not fallen ill.
And the US National Institutes of Health (NIH) said Thursday it was launching a huge trial across more than 12 countries for people exposed to drug-resistant strains of TB.
The study will test a new drug on vulnerable populations such as children and those with weakened immune systems, including HIV-positive people.
– AFP

For just US$7.50 a month, sign up as a subscriber on The Online Citizen Asia (and enjoy ads-free experience on our site) to support our mission to transform TOC into an alternative mainstream press.
Tags: AFP

Related Posts

WHO panel in talks on COVID emergency status
AFP

WHO panel in talks on COVID emergency status

27/01/2023
Chinese property giant Evergrande under ‘tremendous pressure’
China

Chinese property giant Evergrande under ‘tremendous pressure’

14/09/2021
Australia’s capital Canberra to enter virus lockdown
Health

Virus lockdown extended for Australia’s capital

14/09/2021
Messenger RNA COVID vaccines 66% effective against Delta: US study
Health

UK to vaccinate over 12s against COVID

14/09/2021
Politics

Facebook shields VIPs from some of its rules: report

14/09/2021
Malaysian PM, opposition in deal to boost stability
Malaysia

Malaysian PM, opposition in deal to boost stability

14/09/2021
Subscribe
Connect withD
Login
I allow to create an account
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.
DisagreeAgree
Notify of
Connect withD
I allow to create an account
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.
DisagreeAgree
0 Comments
Inline Feedbacks
View all comments

Latest posts

Singapore warns slower economic growth in 2023

Less than 1 in 10 jobs created in first three quarters of 2022 went to Singaporeans?

28/01/2023
Peru Congress rejects president’s plan for early elections

Peru Congress rejects president’s plan for early elections

28/01/2023
UMNO purging members as it sacks former health minister Khairy and suspended ex-defence minister Hishammuddin

UMNO purging members as it sacks former health minister Khairy and suspended ex-defence minister Hishammuddin

28/01/2023
WHO panel in talks on COVID emergency status

WHO panel in talks on COVID emergency status

27/01/2023

Two years after Myanmar coup, UN says situation ‘catastrophic’

27/01/2023
Grab driver supposedly earned $5,227.82 in a week prior CNY, netizens voice worries over his health

Grab driver supposedly earned $5,227.82 in a week prior CNY, netizens voice worries over his health

27/01/2023
Philippines to appeal ICC resumption of drug war probe

ICC grants new inquiry into Manila’s deadly ‘war on drugs’

27/01/2023
Minister refutes claims of Malaysia consulting Singapore on housing policy due to its inefficient civil service

Minister refutes claims of Malaysia consulting Singapore on housing policy due to its inefficient civil service

27/01/2023

Trending posts

Two Indian nationals paid about S$330 and S$730 respectively for forged certificates submitted in their S-Pass application

MOM found issuing EPs meant for foreign PMETs to PRC waitress and general worker

by Correspondent
26/01/2023
36

...

Earning only S$400 a month, delivery-rider turned hawker threw in the towel after two years of running a rojak stall

Earning only S$400 a month, delivery-rider turned hawker threw in the towel after two years of running a rojak stall

by Yee Loon
26/01/2023
24

...

Ho Ching breaks silence over Temasek’s write down of its US$275 million investment in FTX, says it “can afford to be contrarian”

US regulator questions VCs’ due diligence work prior to investing in FTX; Ho Ching says Temasek can afford to be contrarian

by The Online Citizen
24/01/2023
28

...

Indian rupee falls 60% since signing of CECA while Singapore becomes top investor in India

by Correspondent
25/01/2023
55

...

Temasek and GIC reportedly in talks with Adani Group accused of “brazen” market manipulation and accounting fraud

Temasek and GIC reportedly in talks with Adani Group accused of “brazen” market manipulation and accounting fraud

by The Online Citizen
26/01/2023
46

...

TB drug price slashed in global push to thwart killer disease

by onlinecitizen
02/11/2019
0

...

November 2019
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
« Oct   Dec »
  • About Us
  • Subscribe
  • Letter submission
  • Contact Us

© 2006 - 2021 The Online Citizen

No Result
View All Result
  • Opinion
    • Editorial
    • Commentaries
    • Comments
  • Current Affairs
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Civil Society
    • Arts & Culture
    • Consumer Watch
    • NGO
  • Politics
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
  • Lifestyle
    • Travel
  • Subscribers login

© 2006 - 2021 The Online Citizen

wpDiscuz